Analysis of Disturbances in Neurofluid Dynamics in Type I Chiari Malformations
NEUROFLUX-C
1 other identifier
interventional
60
1 country
1
Brief Summary
A global analysis of craniospinal hemodynamics and hydrodynamics is necessary to better understand the pathophysiology of Chiari malformations. This includes an analysis of intraventricular CSF flow, intracranial subarachnoid spaces, foramen magnum, cervical subarachnoid spaces and within the syringomyelia cavity when present. The investigators will also analyze the pulsatility of the cerebellar tonsils in the foramen magnum. Hemodynamic analysis will be performed at the high cervical level (internal carotid and vertebral arteries, jugular veins) and intracranially (carotid and basilar arteries, right sinus and superior longitudinal sinus). This analysis will be made possible by PCMRI acquisitions with slice planes allowing the analysis of the dynamics of the CSF (mesencephalic aqueduct, prepontic cisterns, foramen magnum, at the level of the C2C3 disc, syringomyelia if present), cerebellar tonsils (foramen magnum). The cross-sectional planes for hemodynamic analysis will be at the level of the C2C3 disc (cervical vascular analysis) and upstream of the polygon of Willis (intracranial vascular analysis). The goal is to complement the clinical and morphological investigations with quantitative imaging of cerebrospinal fluid (CSF) and blood flow in the craniospinal system. These flows are potentially altered or causes of this Chiari anomaly. The investigators propose a translational research project of clinical research allowing the analysis of a diagnostic technique by a diagnostic, monocentric, prospective study. After neurosurgical consultation, patients with Chiari malformation will be assigned to a symptomatic Chiari malformation or a non-symptomatic Chiari malformation group. They will be offered to participate in this study after information and informed consent. The allocation between the two groups will be made according to the symptomatic or non-symptomatic nature of the Chiari malformation. After inclusion, the patients will have a morphological MRI and a PCMRI according to the determined slice plans and allowing a global analysis of the craniospinal hemohydrodynamics. Craniospinal hemohydrodynamics in a control population will also be analyzed using the same methodology by PCMRI.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jun 2024
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 24, 2024
CompletedFirst Submitted
Initial submission to the registry
July 9, 2024
CompletedFirst Posted
Study publicly available on registry
July 16, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2027
ExpectedApril 2, 2025
April 1, 2025
9 months
July 9, 2024
April 1, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
CSF Flow
Flow will be measured by the oscillatory volume expressed in mL/cardiac cycle.
day 1
Blood Flow
Flow will be measured by the oscillatory volume expressed in mL/cardiac cycle.
day 1
Study Arms (3)
Symptomatic CMI group
EXPERIMENTALNon-Symptomatic CMI group
EXPERIMENTALControl group
ACTIVE COMPARATORInterventions
patients will benefit from phase contrast sequences complementary to the morphological MRI performed as part of the patient management.
Eligibility Criteria
You may qualify if:
- All patients with major symptomatic or nonsymptomatic CMI
- aged 18 to 50 years
- no previous neurosurgical, neurological, or cardiological history.
- Controls should be age-matched to symptomatic CMI group. They should not have a history of neurosurgery, neurology, or cardiology.
You may not qualify if:
- Patients who are minors or over 50 years of age
- CMI invalidated by our radiological review
- Neurosurgical, neurological or cardiological history
- MRI contraindication
- pregnant, breast-feeding and parturient women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU Amiens Picardie
Amiens, Picardie, 80054, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 9, 2024
First Posted
July 16, 2024
Study Start
June 24, 2024
Primary Completion
April 1, 2025
Study Completion (Estimated)
July 1, 2027
Last Updated
April 2, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share